The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Commentary|Videos|March 13, 2026
Deescalation in Diffuse Large B-Cell Lymphoma
Author(s)Hua-Jay "Jeff" Cherng, MD
Fact checked by: Paige Britt
Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates.
Advertisement
In an interview with Targeted Oncology, Hua-Jay “Jeff” Cherng, MD, assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discussed the details of the SHORTEN-ctDNA trial (NCT06693830).1 Dr Cherng explained how using real-time circulating tumor (ct)DNA monitoring can decide which patients with newly diagnosed diffuse large B-cell lymphoma can safely 'deescalate' their chemotherapy.
REFERENCE
1.ctDNA-guided therapy optimization in newly diagnosed DLBCL. ClinicalTrials.gov. Updated January 23, 2026. Accessed March 11, 2026. https://clinicaltrials.gov/study/NCT06693830
Advertisement
Related to this article
Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Patients with relapsed or refractory CTCL who responded to denileukin diftitox-cxdl experienced improvements in skin-related quality of life and overall well-being in Study 302.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
5